Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients.

LʼHuillier, Arnaud G; Hirzel, Cedric; Ferreira, Victor H; Ierullo, Matthew; Ku, Terrance; Selzner, Nazia; Schiff, Jeffrey; Juvet, Stephen; Miao, Congrong; Schmid, D Scott; Humar, Atul; Kumar, Deepali (2021). Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients. Transplantation, 105(10), pp. 2316-2323. Lippincott Williams & Wilkins 10.1097/TP.0000000000003621

[img]
Preview
Text
Evaluation_of_Recombinant_Herpes_Zoster_Vaccine.95417__1_.pdf - Accepted Version
Available under License Publisher holds Copyright.

Download (1MB) | Preview

BACKGROUND

Immunization of VZV-seronegative solid organ transplant (SOT) patients using the live-attenuated varicella vaccine is generally contraindicated, leaving no widely applicable immunization option. The recombinant subunit herpes zoster vaccine (RZV) is indicated for VZV seropositive persons to prevent shingles but could potentially also protect VZV-seronegative persons against varicella. We performed a safety and immunogenicity evaluation of RZV in VZV-seronegative SOT recipients as an option for protection.

METHODS

VZV-seronegative adult SOT patients with no history of varicella/shingles vaccine or disease were given 2 doses of RZV vaccine 2-6 months apart. Blood was drawn prevaccination (V1), prior to the second dose (V2) and 4 weeks after second dose (V3). Humoral (anti-gE) and cell-mediated immunity was evaluated, with polyfunctional cells defined as cells producing ≥2 cytokines.

RESULTS

Among 31 eligible VZV-seronegative SOT patients screened, 23 were enrolled. Median age was 38 years and median time since transplant procedure was 38 years. The most frequent transplant types were liver (35%) and lung (30%). Median anti-gE levels significantly increased from V1 to V3 (p=0001) and V2 to V3 (p<0001), even though only 55% had a positive seroresponse. Median polyfunctional CD4 T-cells counts increased from V1 to V2 (54/10 vs 104/10 cells; p=0041), and from V2 to V3 (380/10; p=0002). Most adverse events were mild with no rejection episodes.

CONCLUSION

RZV was safe and elicited significant humoral and cellular responses in VZV-seronegative SOT patients, and has the potential to be considered as a preventive strategy against primary varicella.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Infectiology

UniBE Contributor:

Hirzel, Cédric

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0041-1337

Publisher:

Lippincott Williams & Wilkins

Language:

English

Submitter:

Annelies Luginbühl

Date Deposited:

20 Apr 2021 09:36

Last Modified:

02 Oct 2021 01:31

Publisher DOI:

10.1097/TP.0000000000003621

PubMed ID:

33528118

BORIS DOI:

10.7892/boris.152218

URI:

https://boris.unibe.ch/id/eprint/152218

Actions (login required)

Edit item Edit item
Provide Feedback